Acta dermato-venereologica最新文献_第2页

Flare-ups: New Insights into the Burden of Pain in Hidradenitis Suppurativa.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-18 DOI: 10.2340/actadv.v105.43124

Florian Regensberger, Fiona André, Matthias Schmuth

引用次数: 0

Widespread Rash with Localized Sparing: A Quiz.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-18 DOI: 10.2340/actadv.v105.43058

Outi Varpuluoma

引用次数: 0

Systemic Targeted Therapies in Patients with Relapsed/Refractory Advanced Stage Cutaneous T-cell Lymphoma: A Real-world Single-centre Case Series.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-13 DOI: 10.2340/actadv.v105.40952

Signe Hedebo, Martin B Pedersen, Lise M Lindahl, Aska Drjlevic-Nielsen, Claus Johansen, Francesco D'Amore, Lars Iversen, Rikke Bech

{"title":"Systemic Targeted Therapies in Patients with Relapsed/Refractory Advanced Stage Cutaneous T-cell Lymphoma: A Real-world Single-centre Case Series.","authors":"Signe Hedebo, Martin B Pedersen, Lise M Lindahl, Aska Drjlevic-Nielsen, Claus Johansen, Francesco D'Amore, Lars Iversen, Rikke Bech","doi":"10.2340/actadv.v105.40952","DOIUrl":"https://doi.org/10.2340/actadv.v105.40952","url":null,"abstract":"Cutaneous T-cell lymphomas are a heterogeneous group of non-Hodgkin lymphomas. Early stages are often controlled with skin-directed therapy, such as topical corticosteroids, topical chlormethine gel, or UV therapy, whereas advanced stages often warrant a more aggressive approach with systemic antibody targeted therapy including mogamulizumab, brentuximab vedotin, or alemtuzumab. A retrospective cohort case series of 27 patients from Aarhus University Hospital, Denmark is presented, evaluating real-world outcomes of patients with cutaneous T-cell lymphomas treated with intravenous systemic targeted therapies from 2013 to 2023. The median age was 72 and the majority had Sézary syndrome or mycosis fungoides. All patients had relapsed/refractory advanced stage cutaneous T-cell lymphoma. Six patients received mogamulizumab, 12 patients received brentuximab vedotin, and 15 patients received alemtuzumab. Six patients received more than 1 of the systemic targeted treatments. Overall response rates were 78% for mogamulizumab, 65% for brentuximab vedotin, and 61% for alemtuzumab. Median time to progression was 2.5, 4, and 11 months, respectively. In conclusion, this paper offers a unique perspective on the complexities of clinical practice when managing advanced-stage cutaneous T-cell lymphomas and demonstrates the effectiveness of the therapies described, with particular emphasis on the promising results observed with alemtuzumab administered in a low-dose protocol.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv40952"},"PeriodicalIF":3.5,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Black Tumour on the Face with a Histological Rippled Pattern: A Quiz.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-12 DOI: 10.2340/actadv.v105.43111

Kimi Iinuma, Kazuyasu Fujii, Shunya Usui, Yoshihito Itani, Atsushi Otsuka

引用次数: 0

Unilateral Maculopapular Rash in a Child: A Quiz.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-12 DOI: 10.2340/actadv.v105.43059

Katarzyna Jankowska, Jozef Kokoszka, Jacek C Szepietowski

引用次数: 0

Patient Needs and Treatment Goals in Chronic Atopic Pruritus: Does Eczema Make a Difference?

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-12 DOI: 10.2340/actadv.v105.42773

Svenja Müller, Claudia Zeidler, Christian Mess, Stefan M Kahnert, Bernd Löwe, Angelika Weigel, Felix Witte, Volker Huck, Lynhda Nguyen, Matthias Augustin, Gina Frank, Konstantin Agelopoulos, Henning Wiegmann, Ansgar Köchel, Rupert Conrad, Gudrun Schneider, Stefan W Schneider, Sonja Ständer, Inga Hansen-Abeck, Finn Abeck

{"title":"Patient Needs and Treatment Goals in Chronic Atopic Pruritus: Does Eczema Make a Difference?","authors":"Svenja Müller, Claudia Zeidler, Christian Mess, Stefan M Kahnert, Bernd Löwe, Angelika Weigel, Felix Witte, Volker Huck, Lynhda Nguyen, Matthias Augustin, Gina Frank, Konstantin Agelopoulos, Henning Wiegmann, Ansgar Köchel, Rupert Conrad, Gudrun Schneider, Stefan W Schneider, Sonja Ständer, Inga Hansen-Abeck, Finn Abeck","doi":"10.2340/actadv.v105.42773","DOIUrl":"10.2340/actadv.v105.42773","url":null,"abstract":"Chronic pruritus (≥ 6 weeks) is a frequent symptom in atopic diseases, with phenotypes ranging from non-lesional skin to inflammatory diseases like atopic dermatitis. Data on patients' needs and treatment goals depending on the skin phenotype and disease burden are limited. This study aimed to analyse the impact of distinct phenotypes of chronic atopic pruritus on disease burden and treatment goals. Another objective was to investigate whether the disease burden influences the treatment goals. Patient-reported outcomes of 1,086 adult patients (n = 529 with atopic dermatitis, n = 557 with chronic pruritus on non-lesional skin with atopic skin diathesis) were analysed age- and gender-matched (mean age 49.7 ± 19.0 years; n = 605 female [55.7%]), comparing pruritus intensity (Numeric Rating Scale), quality of life (Dermatology Life Quality Index, ItchyQol), anxiety and depression (Hospital Anxiety and Depression Scale), and patient needs (Patient Needs Questionnaire of the Patient Benefit Index-Pruritus). Although the disease burden was significantly higher in patients with atopic dermatitis (prolonged disease duration, increased quality of life impairment, higher pruritus intensity), the treat-ment goals of both phenotypes matched in 92.6%. The most important needs were to no longer experience itching, find a clear diagnosis and therapy, and have confidence in the therapy.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv42773"},"PeriodicalIF":3.5,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143612935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pemphigoid with Autoantibodies against p200 and all Subunits of Laminin 332 Associated with Drug Eruption Caused by Piperacillin/tazobactam.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-12 DOI: 10.2340/actadv.v105.41369

Hanako Miyahara, Rie Honda, Shusaku Ito, Norito Ishii, Toshifumi Nomura

引用次数: 0

Bullous Haemorrhagic Vasculitis Associated with Adalimumab in a Child with Juvenile Idiopathic Arthritis.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-12 DOI: 10.2340/actadv.v105.42482

Valeria Biasotti, Dalila Iacono, Chiara Pilotto, Barbara Bigucci, Giorgia Martini

引用次数: 0

Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-12 DOI: 10.2340/actadv.v105.42275

Laura Calabrese, Elisa Cinotti, Martina D'Onghia, Alessandra Cartocci, Pietro Rubegni, François Maccari, Claire Boulard, Ziad Reguiai, Pierre-André Becherel, Caroline Jacobzone, Edouard Begon, Charlotte Fite, Beatrice Walls, Anne Laure Liegeon, Josiane Parier, Guillaume Chaby, Jean-Luc Perrot

{"title":"Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study.","authors":"Laura Calabrese, Elisa Cinotti, Martina D'Onghia, Alessandra Cartocci, Pietro Rubegni, François Maccari, Claire Boulard, Ziad Reguiai, Pierre-André Becherel, Caroline Jacobzone, Edouard Begon, Charlotte Fite, Beatrice Walls, Anne Laure Liegeon, Josiane Parier, Guillaume Chaby, Jean-Luc Perrot","doi":"10.2340/actadv.v105.42275","DOIUrl":"https://doi.org/10.2340/actadv.v105.42275","url":null,"abstract":"Tralokinumab is a monoclonal antibody selectively targeting IL-13, approved for moderate-to-severe atopic dermatitis (AD), for which real-world data are scarce. This prospective, observational, multicentric study aimed to assess the long-term effectiveness and safety of tralokinumab in patients with AD in a real-world setting. Primary outcomes included 50%, 75%, and 90% improvement in Eczema Area and Severity Index score (EASI50, EASI75, EASI90, respectively) and improvements in Dermatology Life Quality Index (DLQI) at 1 year. A total of 136 patients with AD were enrolled in the study; data at 1-year follow-up were available for 111 patients. After 1 year, 68.5% and 33.3% of patients achieved an EASI75 and EASI90, respectively. A significantly higher percentage of patients with than without foot involvement achieved EASI50 (p = 0.009) and EASI75 (p = 0.022). Similarly, hand involvement was significantly associated with higher EASI50 response (p = 0.005). Median DLQI score decreased from 9.00 (interquartile range (IQR): 6.00, 13.75) to 1.00 (IQR: 0.00, 4.00) after 1 year of treatment. Adverse events included blepharitis (n = 10), conjunctivitis (n = 6), and injection-site reactions (n = 2). Tralokinumab can be an effective and safe treatment for patients with moderate-to-severe AD. Involvement of certain body areas, such as hands and feet, might positively predict a clinical response to tralokinumab.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv42275"},"PeriodicalIF":3.5,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143612932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Features, Diagnosis and Treatment of Different Types of Paediatric Pemphigus.

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-03-09 DOI: 10.2340/actadv.v105.42776

An-Wei Chen, Li Liu, Huan Yang, Xiao-Yan Luo, Juan Xiang

{"title":"Clinical Features, Diagnosis and Treatment of Different Types of Paediatric Pemphigus.","authors":"An-Wei Chen, Li Liu, Huan Yang, Xiao-Yan Luo, Juan Xiang","doi":"10.2340/actadv.v105.42776","DOIUrl":"10.2340/actadv.v105.42776","url":null,"abstract":"Pemphigus is a rare and life-threatening autoimmune disease that is easily ignored in children. This study aimed to attract attention to pemphigus in the paediatric population for better understanding and recognition of the clinical characteristics and management in children's different subtypes of pemphigus. The case series involved a retrospective record review of 3 patients who were referred to a department of dermatology from January 2022 to January 2024. All patients experienced a delayed diagnosis, but were eventually definitively diagnosed with pemphigus vulgaris, pemphigus foliaceus, and pemphigus erythematosus, because they all have intraepidermal blisters and elevated serum antibodies against Dsg1/Dsg3. In all 3 cases, systemic corticosteroids were used in combination with or without steroid-sparing adjuvants. The patient with pemphigus vulgaris experienced a recurrence due to discontinuous treatment; the other 2 patients achieved mostly remission after treatment, with the length of follow-up ranging from 5 to 12 months. Pemphigus in children has its own clinical characteristics and similar literature concerning improved strategies for clinical assessment and treatments are reviewed and discussed.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv42776"},"PeriodicalIF":3.5,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0